INTRODUCTION AND OBJECTIVES:
Recent studies have reported that African American (AA) men are at an increased risk of progression on Active Surveillance (AS) compared to Caucasians (CA). However, many of these studies are based on relatively few AA, have limited follow-up and may be subject to detection biases related to compliance with AS regimens or biopsy recommendations. The objective of this study was to evaluate whether race is associated with risk of reclassification in a well-established prospective AS cohort that utilizes protocol-driven PSA measurements and surveillance biopsies.
METHODS: Data are from the multicenter Canary Prostate Active Surveillance Study (PASS). PSAs are collected every 3 months and surveillance biopsies are protocol-recommended at 6-12 months after initial diagnosis, 24 months, and every 2 years thereafter. Men included in this study had Gleason grade 3þ3 or 3þ4 at diagnosis, < 5 years between diagnosis and enrollment, and had undergone ! 1 surveillance biopsy. Cox proportional hazards models were used to examine differences between AA and CA men and time to reclassification, defined as an increase in Gleason score on subsequent biopsy and adverse pathology at prostatectomy, defined as pT3a or greater or Gleason grade group 3 or greater.
RESULTS: Of the 1,315 men in this study, 89(7%) were AA and 1,226(93%) were CA. Compared to CA, AA had significantly higher median PSA and PSA density at diagnosis (5.6 vs 4.9, p<0.001; 0.14 vs 0.11, p[0.01). Overall treatment rates were comparable between AAs and CAs, though AAs were more likely to undergo radiation and CAs were more likely to undergo radical prostatectomy (57% vs 38% and 56% vs 43%, respectively, p>0.05 for both). In multivariate models adjusted for diagnostic biopsy and clinical variables, AA race was not significantly associated with the risk of reclassification (HR[1.16, p[0.45) . Among men who had a prostatectomy, the rate of adverse pathology was similar for AA and CA (31% vs 27%, p[0.76) .
CONCLUSIONS: In a prospective cohort of men on AS who follow a standardized protocol of regular PSA and biopsy, AA race was not associated with risk of adverse pathologic reclassification or adverse pathology at prostatectomy. These results provide support for the choice of AS for AA men and suggest that biases related to racial disparity in screening, access to care, and patterns of treatment may contribute to conflicting results from prior studies. INTRODUCTION AND OBJECTIVES: Patient-centered delivery of healthcare and shared decision-making have become increasingly important concepts over the past several decades, yet current tools lack critical information for risk counseling. We sought to develop a risk calculator that provides clinicians and patients with contextualized risk estimates for upgrading on biopsy while enrolled in AS. We sought to develop and evaluate the usability of a risk calculator interface that would convey personalized information regarding risk of upgrading on AS.
METHODS: A risk calculator was developed that included increased contextual information regarding an individual patient's risk, including how specific variables compared with the model cohort and the patient's relative risk compared to other similar men. The usability of this calculator was then assessed among urologists using case-based scenarios. A survey was sent to urology residents, fellows, and attendings. We assessed accuracy in interpreting the calculator and participant-rated clinical usefulness of the calculator.
RESULTS: The individual risk calculator has 3 columns: 1) patient variables; 2) how the patient's values compare with the cohort; and 3) the patient's relative risk compared with the cohort (Figure 1 ). There were 17 respondents to the usability survey (5 residents, 3 fellows, 9 attendings). Among attending urologists, 78% had completed oncology-focused fellowships. Accuracy for interpreting individual patient outcomes was 92%. Clinicians were confident in their ability to use the calculator 70% of the time. Overall, 70% of respondents stated that such a risk calculator would be useful in clinical practice.
CONCLUSIONS: The PASS Risk Calculator interface improves upon previously-published risk calculators for prediction of upgrading on AS by providing more personalized tailored information to both clinicians and patients. The interface derives from a new model for risk prediction. More work is required to determine if clinical implementation of the risk calculator is associated with improved patient-centered outcomes related to decision-making on AS. 
